BRCA Mutations Treatment Market size was valued at USD 13 Million in 2023 and is anticipated to exceed USD 23 Billion by the end of 2036, registering over 3% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of BRCA mutations treatment is evaluated at USD 15 Million.
The increasing prevalence of cancer patients globally will exponentially propel the growth of the BRCA mutations treatment market by the end of 2036. According to WHO, 20 million new examples of cancer and 9.7 million deaths from the disease are assumed for 2022. 53.5 million people were assumed to still live their lives five years after receiving a cancer diagnosis. One in five people will have cancer at some point in their lives; one in nine men and one in twelve women will die from the sickness.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2036 |
|
CAGR |
3% |
|
Base Year Market Size (2023) |
USD 13 Million |
|
Forecast Year Market Size (2036) |
USD 23 Million |
|
Regional Scope |
|
Treatment Type (Surgery, Chemotherapy, Platinum Agents, PARP Inhibitors)
Chemotherapy segment is likely to hold more than 68% BRCA mutations treatment market share by 2036 because of the increasing uses of chemotherapy for the treatment of cancer. According to Cancer World’s statistics, in 2018, 9.8 million out of 17 million new cancer cases worldwide, whereas 57.7% required chemotherapy. By 2040, there will be 26 million new cases of cancer worldwide, of which 53% (15 million) or +5.2 million new cases from 2018 would require chemotherapy.
An aberrant state of cells known as cancer results in unchecked cell growth and aggressive malignancies that kill millions of people annually. Their knowledge of the disease is expanding rapidly due to our growing understanding of the molecular mechanism(s) behind its growth. This has resulted in the development of numerous novel therapeutic approaches and the subsequent testing of them.
Cancer Type (Breast Cancer, Ovarian Cancer)
By 2036, breast cancer segment is set to dominate over 80% BRCA mutations treatment market share owing to the rising prevalence of breast cancer globally. 2.3 million women worldwide had a breast cancer diagnosis in 2022, and 670,000 people died from the disease. All across the world, breast cancer influences women at all ages after puberty, however, its frequency increases with age.
Aging, obesity, heavy alcohol consumption, radiation exposure history, family history of breast cancer, reproductive history (including age at first pregnancy and menstruation onset), tobacco use, and postmenopausal hormone therapy are some of the factors that raise the risk of breast cancer. Other than age (over 40) and gender (female), women without any other known breast cancer risk factor account for around half of all cases of breast cancer.
Our in-depth analysis of the global BRCA mutations treatment market includes the following segments:
|
Treatment Type |
|
|
Cancer Type |
|
|
End-Users |
|
North American Market Statistics
North America in BRCA mutations treatment market is likely to hold more than 39% revenue share by 2036. This growth will be noticed owing to the increasing advancement in technology for the treatment of cancer in this region. There have been significant investments made by the public and commercial sectors. According to the National Library of Medicine, with expenditures topping USD 4.7 billion, or about 20% of the whole NIH budget, the National Cancer Institute (NCI) is now the biggest institution supported by the National Institute on Health (NIH).
The U.S. will hold a good position in the BRCA mutations treatment market because of the rising advancement in healthcare infrastructure. The United States' healthcare system was placed sixth in the world in the 2021 World Index on Healthcare Innovation, which was compiled by the Foundation for Research on Equal Opportunity (FREOPP).
The Canadian BRCA mutation treatment sector will increase rapidly because of the increasing chronic disease in this country. In 2021, 45.1% of Canadians had at least one serious chronic illness.
APAC Market Analysis
The BRCA mutations treatment market in the APAC region will also encounter huge growth during the estimated timeframe and will hold the second position owing to the increasing frequency of ovarian cancer in this region. One of the most prevalent diseases in women is ovarian cancer, which is frequently detected as an advanced stage due to the early signs of the disease's modest symptoms. Over 39,000 people lost their lives to OC in the APAC region in 2020, while over 57,000 new cases were recorded.
In China, the industry will increase because of the rising government initiatives to cure cancer. The National Cancer Center (NCC) of China estimates that 4,064,000 newly diagnosed cases of cancer were recorded.
South Korea will also notice a huge expansion because of the unique advent of chemotherapies in this country. With almost 2 million cancer survivors in Korea recently, the Korean Cancer Society projected that up to 260,000 Koreans may receive a new cancer diagnosis in 2021.
The Japanese BRCA mutations treatment market will rise because of the rising number of geriatric patients in this country. As per the National Institute of Population and Social Security Research, by 2040, the proportion of the Japanese population aged 65 and above is predicted to be 34.8%. The home healthcare services have also increased in demand.
A number of end-use companies are available that deal with BRCA mutation treatment. Here are some majorities of key players;
Roche Holding AG, declared the U.S. Food and Drug Administration (FDA) acceptance of the cobas Malaria test for utilization on the cobas® 6800/8800 Systems. This accepted test can help healthcare professionals in limiting the possible risks of patient infection from imbued blood materials. The cobas Malaria test gives a highly sensitive and particular solution to assist confirm that infected blood units are eliminated from the blood supply.
Roche Holding AG, declared that the U.S. Food and Drug Administration (FDA) has accepted Xolair (omalizumab) for the limitation of allergic answers, comprising anaphylaxis, that may appear with accidental involvement in one or more foods in adults and pediatric patients aged 1 year and older with IgE-intervened food allergy.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?